Bzowska Agnieszka, Koellner Gertraud, Wielgus-Kutrowska Beata, Stroh Albrecht, Raszewski Grzegorz, Holý Antonin, Steiner Thomas, Frank Joachim
Department of Biophysics, Institute of Experimental Physics, University of Warsaw, Zwirki i Wigury 93, 02-089 Warsaw, Poland.
J Mol Biol. 2004 Sep 17;342(3):1015-32. doi: 10.1016/j.jmb.2004.07.017.
The crystal structure of the binary complex of trimeric purine nucleoside phosphorylase (PNP) from calf spleen with the acyclic nucleoside phosphonate inhibitor 2,6-diamino-(S)-9-[2-(phosphonomethoxy)propyl]purine ((S)-PMPDAP) is determined at 2.3A resolution in space group P2(1)2(1)2(1). Crystallization in this space group, which is observed for the first time with a calf spleen PNP crystal structure, is obtained in the presence of calcium atoms. In contrast to the previously described cubic space group P2(1)3, two independent trimers are observed in the asymmetric unit, hence possible differences between monomers forming the biologically active trimer could be detected, if present. Such differences would be expected due to third-of-the-sites binding documented for transition-state events and inhibitors. However, no differences are noted, and binding stoichiometry of three inhibitor molecules per enzyme trimer is observed in the crystal structure, and in the parallel solution studies using isothermal titration calorimetry and spectrofluorimetric titrations. Presence of phosphate was shown to modify binding stoichiometry of hypoxanthine. Therefore, the enzyme was also crystallized in space group P2(1)2(1)2(1) in the presence of (S)-PMPDAP and phosphate, and the resulting structure of the binary PNP/(S)-PMPDAP complex was refined at 2.05A resolution. No qualitative differences between complexes obtained with and without the presence of phosphate were detected, except for the hydrogen bond contact of Arg84 and a phosphonate group, which is observed only in the former complex in three out of six independent monomers. Possible hydrogen bonds observed in the enzyme complexed with (S)-PMPDAP, in particular a putative hydrogen bonding contact N(1)-H cdots, three dots, centered Glu201, indicate that the inhibitor binds in a tautomeric or ionic form in which position N(1) acts as a hydrogen bond donor. This points to a crucial role of this hydrogen bond in defining specificity of trimeric PNPs and is in line with the proposed mechanism of catalysis in which this contact helps to stabilize the negative charge that accumulates on O(6) of the purine base in the transition state. In the present crystal structure the loop between Thr60 and Ala65 was found in a different conformation than that observed in crystal structures of trimeric PNPs up to now. Due to this change a new wide entrance is opened into the active site pocket, which is otherwise buried in the interior of the protein. Hence, our present crystal structure provides no obvious indication for obligatory binding of one of the substrates before binding of a second one; it is rather consistent with random binding of substrates. All these results provide new data for clarifying the mechanism of catalysis and give reasons for the non-Michaelis kinetics of trimeric PNPs.
小牛脾来源的三聚体嘌呤核苷磷酸化酶(PNP)与无环核苷膦酸抑制剂2,6 - 二氨基 -(S)-9 - [2 -(膦酰甲氧基)丙基]嘌呤((S)-PMPDAP)的二元复合物晶体结构在空间群P2(1)2(1)2(1)中以2.3Å分辨率解析。在钙离子存在下获得了该空间群中的晶体,这是首次在小牛脾PNP晶体结构中观察到这种空间群的结晶。与先前描述的立方空间群P2(1)3不同,在不对称单元中观察到两个独立的三聚体,因此,如果存在的话,可以检测到形成生物活性三聚体的单体之间可能存在的差异。由于在过渡态事件和抑制剂中记录的三分之一位点结合,预计会存在这种差异。然而,未观察到差异,并且在晶体结构以及使用等温滴定量热法和荧光光谱滴定法的平行溶液研究中,观察到每个酶三聚体结合三个抑制剂分子的结合化学计量。已表明磷酸盐的存在会改变次黄嘌呤的结合化学计量。因此,该酶也在(S)-PMPDAP和磷酸盐存在下在空间群P2(1)2(1)2(1)中结晶,并将所得的二元PNP/(S)-PMPDAP复合物结构在2.05Å分辨率下进行了精修。除了仅在六个独立单体中的三个中观察到的前一个复合物中Arg84与一个膦酸酯基团的氢键接触外,未检测到有和没有磷酸盐存在时获得的复合物之间的定性差异。在与(S)-PMPDAP复合的酶中观察到的可能的氢键,特别是假定的以Glu201为中心的N(1)-H∙∙∙氢键接触,表明抑制剂以互变异构体或离子形式结合,其中N(1)位置充当氢键供体。这表明该氢键在定义三聚体PNP的特异性中起关键作用,并且与提出的催化机制一致,在该机制中这种接触有助于稳定过渡态嘌呤碱基O(6)上积累的负电荷。在当前晶体结构中,发现Thr60和Ala65之间的环与迄今为止在三聚体PNP晶体结构中观察到的构象不同。由于这种变化,一个新的宽阔入口通向活性位点口袋,否则该口袋埋在蛋白质内部。因此,我们目前的晶体结构没有提供明显迹象表明在第二个底物结合之前必须先结合一个底物;它更符合底物的随机结合。所有这些结果为阐明催化机制提供了新数据,并为三聚体PNP的非米氏动力学提供了原因。